CVE:NDVA

Indiva Stock Forecast, Price & News

C$0.32
-0.01 (-1.54 %)
(As of 07/26/2021 03:57 PM ET)
Add
Compare
Today's Range
C$0.32
C$0.33
50-Day Range
C$0.32
C$0.46
52-Week Range
C$0.19
C$0.74
Volume153,232 shs
Average Volume322,503 shs
Market CapitalizationC$43.52 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NDVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Indiva and its competitors with MarketBeat's FREE daily newsletter.


About Indiva

Indiva Limited operates as a licensed producer of cannabis products in Canada. It creates premium pre-rolls, flower, capsules, and edible products, as well as provides production and manufacturing services to peer entities. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Ruby Cannabis Sugar, Sapphire Cannabis Salt, Artisan Batch, and other powered by INDIVA products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.32 out of 5 stars

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Indiva (CVE:NDVA) Frequently Asked Questions

Is Indiva a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indiva in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Indiva stock.
View analyst ratings for Indiva
or view top-rated stocks.

What stocks does MarketBeat like better than Indiva?

Wall Street analysts have given Indiva a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Indiva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Indiva's stock been impacted by COVID-19?

Indiva's stock was trading at C$0.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NDVA stock has increased by 23.1% and is now trading at C$0.32.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for NDVA?

1 analysts have issued 12-month price targets for Indiva's stock. Their forecasts range from C$0.63 to C$0.63. On average, they expect Indiva's share price to reach C$0.63 in the next twelve months. This suggests a possible upside of 96.9% from the stock's current price.
View analysts' price targets for Indiva
or view top-rated stocks among Wall Street analysts.

Who are Indiva's key executives?

Indiva's management team includes the following people:
  • Mr. Carmine Marotta, Co-Founder, Pres, CEO & Director
  • Ms. Jennifer Welsh, Chief Financial Officer
  • Mr. Dave Paterson, Chief Commercial Officer
  • Mr. Robert William Carse, Chief Operating Officer
  • Ms. Kate Abernathy, VP of Communications
  • Ms. Sherry Kelly, Director of Human Resource
  • Mr. Tomasz Borowicz, Chief Brand Officer
  • Ms. Leah Thiel, Marketing Director
  • Mr. Eric Van Dam, Sales Director
  • Mr. Alejandro Vernaza, Sales Director

Who are some of Indiva's key competitors?

What other stocks do shareholders of Indiva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indiva investors own include (CGC), Curaleaf (CURLF), Dynavax Technologies (DVAX), Heat Biologics (HTBX), OrganiGram (OGI), Vaxart (VXRT), Aurora Cannabis (ACB), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA) and Energy Transfer (ET).

What is Indiva's stock symbol?

Indiva trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NDVA."

How do I buy shares of Indiva?

Shares of NDVA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Indiva's stock price today?

One share of NDVA stock can currently be purchased for approximately C$0.32.

How much money does Indiva make?

Indiva has a market capitalization of C$43.52 million and generates C$18.86 million in revenue each year.

How many employees does Indiva have?

Indiva employs 147,000 workers across the globe.

What is Indiva's official website?

The official website for Indiva is indiva.ca.

How can I contact Indiva?

The company can be reached via phone at 888-649-6686.


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.